FGL (FG Loop Peptide)

NCAM-Derived Peptide · Synaptic Plasticity & Neuroprotection

Overview

FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models.

FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.

Enhances memory consolidation and spatial learning in animal models through FGFR1-mediated synaptic plasticity.

Preclinical evidence suggests potential to counteract age-related cognitive decline via neurogenesis and synaptic support.

Animal studies demonstrate reduced infarct volume and improved functional outcomes following ischemic injury.

Shows protective effects in preclinical models of Alzheimer's disease and other neurodegenerative conditions.

Mechanism

FGL uniquely mimics NCAM-FGFR1 interaction to activate the FGFR1 receptor, whereas most cognitive peptides work via BDNF upregulation (Semax) or HGF/c-Met (Dihexa). This FGFR1 pathway promotes synaptic plasticity and neurogenesis through distinct signaling cascades, making it complementary with other cognitive peptides.

Research areas

FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models.
FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.
Enhances memory consolidation and spatial learning in animal models through FGFR1-mediated synaptic plasticity.
Preclinical evidence suggests potential to counteract age-related cognitive decline via neurogenesis and synaptic support.
Animal studies demonstrate reduced infarct volume and improved functional outcomes following ischemic injury.
Shows protective effects in preclinical models of Alzheimer's disease and other neurodegenerative conditions.
Promotes long-term potentiation and strengthens synaptic connections through FGFR1 activation.
Stimulates the generation of new neurons in the hippocampus in animal models.

Research notes

Injection site reactions (redness, mild swelling, irritation)
Signs of allergic reaction (rash, difficulty breathing, swelling)
Persistent or worsening injection site reactions
Unusual neurological symptoms (severe headache, dizziness, vision changes)
Pregnancy or breastfeeding
Known peptide or NCAM-related compound allergies
Very limited human safety data -- use with caution under medical supervision

References

FAQs

What evidence supports FGL for human cognitive enhancement?

FGL research is primarily in animal models, where it enhances spatial memory, promotes hippocampal neurogenesis, and protects neurons from excitotoxicity. No human clinical trials exist yet. Evidence remains preclinical, making it a high-risk, exploratory peptide suitable only for research contexts with medical awareness of limited human safety data.

Can FGL help with age-related cognitive decline?

Animal studies suggest FGL could counteract age-related cognitive decline through neurogenesis stimulation and synaptic support. However, no human studies confirm this. Preclinical evidence is promising but insufficient to make clinical claims for aging—available research is entirely in younger animal models.

Is FGL injectable the only available form?

Currently, FGL is available primarily in lyophilized powder form for subcutaneous injection. Oral or nasal formulations exist theoretically but lack research validation. Subcutaneous injection has been studied in animals, making it the most established route, though human administration data is essentially nonexistent.